5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITT
MA41238AInactive Publication Date: 2017-11-01LES LAB SERVIER SA +1
0 Cites 0 Cited by
Patent Information
- Application Number
- MA41238
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-12-18
- Filing Date
- 2015-12-18
- Publication Date
- 2017-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Current treatments for osteoarthritis, such as NSAIDs and joint replacement, fail to halt disease progression or promote cartilage regeneration, and existing ADAMTS inhibitors have off-target effects on structurally related MMPs like MMP-8 and MMP-12.
Method used
Development of novel hydantoin compounds that selectively inhibit ADAMTS-5, a key protease in cartilage degradation, to treat inflammatory conditions and osteoarthritis while minimizing effects on other MMPs.
Benefits of technology
The hydantoin compounds effectively inhibit ADAMTS-5, potentially slowing cartilage damage and reducing pain in osteoarthritis without the undesirable side effects associated with broad-spectrum MMP inhibitors.
✦ Generated by Eureka AI based on patent content.
Abstract
the present invention relates to compounds of formula (i), where r, r 2 , r 3a , r 3b and cy are as defined in the description. The present invention relates to Adamts inhibitory compounds, methods for their production, pharmaceutical compositions comprising them, and methods for the prophylaxis and / or treatment of inflammatory conditions and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis.<!--endfragment-->
Need to check novelty before this filing date? Find Prior Art